Felicitex Therapeutics, Inc., a drug discovery company specializing in discovery and development of cancer treatments and diagnostic assays focused on quiescent cancer cells.

Biotech/Pharma partnering in Emerging Markets. Licensing, M&A, consulting on new oncology drug development programs in Emerging countries

• Project leader, responsible for all phases of pre-clinical drug discovery projects: target discovery, identification, validation and characterization of leads.• Led multi-functional teams through discovery, lead identification and optimization phases, Successfully achieved milestones. Independently planned and managed aggressive research and product development timelines.• Developed cell-based in vitro assays; PK/PD, in vivo models.• Managed collaborations and developed applications for novel products. Successfully completed and published studies.• Performed due diligence of novel oncology drug target and drug candidates and made objective recommendations to Business Development regarding corporate acquisitions and technology licensing.• Successfully managed a group of PhD and junior R&D scientists.

Investment opportunity identification and evaluation for Licensing and M&A;

• Developed in vitro and in vivo characterization of the novel Hsp90 inhibitor including PK/PD characterization of the drug candidate.• Developed ELISA HTS assays.• Studied the function of the Hsp90 family members in oncogenic transformation (siRNA, antisense DNA, RT-PCR, Western blots, Flow Cytometry)

• Developed analytical methods for characterization of DNAs, RNAs and their metabolites in biological fluids. Successfully published manuscripts and filed patents.• Participated in different phases of drug development with emphasis on PK/PD, drug metabolism.• Responsible for QC analysis of drug candidate (Capillary Gel Electrophoresis, HPLC)